OBJECTIVES: There are several potential investigational therapies for Alzheimer’s disease with inconclusive evidence of efficacy. This network meta-analysis was conducted to compare these treatments indirectly and prioritize future research directions. METHODS: Indirect comparison of MMSE scores was conducted using STATA-13. The probability of each treatment for being most efficacious regimen was calculated using the difference against placebo, and counting the proportion of iterations of the Markov chain. RESULTS: A total of twenty-two studies were included. Overall 2,974 individuals were randomized to vitamins (cyanocobalamin, folic-acid, tocopherol), NSAIDs (indomethacin, piroxicam, ibuprofen, diclofenac+misoprostol), statins (atorvastatin, pravastatin, simvastatin), omega-3 fatty acids, sertraline, PBT2, xanthenes derivatives (denbufylline, propentofylline) or placebo. Results showed that simvastatin was the most efficacious regimen with a difference (95% prediction interval) of 0.91 (-3.26, 5.09) against denbufylline; 2.44 (-1.69, 6.57) against omega-3 fatty acid; 1.21 (-4.13, 6.55) against PBT2; 1.71 (-2.44, 5.86) against propentofylline; 0.58 (-3.82, 4.98) against atorvastatin; 2.76 (-1.27, 6.79) against cyanocobalamin; 3.48 (-1.31, 8.28) against diclofenac+misoprostol; 2.30 (-1.48, 6.08) against folic acid; 2.81 (-1.20, 6.82) against ibuprofen; 4.83 (-0.53, 10.20) against indomethacin; 2.21 (-0.98, 5.40) against placebo; 2.71 (-2.02, 7.44) against sertraline; and 2.61 (-0.89, 6.12) against tocopherol. The cumulative probabilities for being the best treatment were: simvastatin (39.4%), atorvastatin (23.0%), PBT2 (17.2%), denbufylline (12.9%), propentofylline (3.5%) sertraline (1.6%), other treatments (<1%). CONCLUSIONS: Of all the unapproved potential treatments of Alzheimer’s, statins and PBT2 showed a superior efficacy. Therefore, future further clinical investigations should consider statins and PBT2 as preferred candidates.